Investor mix
12 investors on record; lead investors include Orbimed; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 9 | 75% |
| Private equity | 2 | 17% |
| Bank & private debt | 1 | 8% |
Developer of drugs for treating cardiovascular and renal diseases
12 investors on record; lead investors include Orbimed; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 9 | 75% |
| Private equity | 2 | 17% |
| Bank & private debt | 1 | 8% |